Cobra Biologics Announces Scale-Up Collaboration

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015
Volume 11
Issue 10

Cobra Biologics and the University of Manchester announce a collaboration to improve industrial scale-up of mammalian cell bioprocessing.

Cobra Biologics and Alan Dickson, professor of biotechnology at The University of Manchester (UoM) announced on Sept. 24, 2015 a two-year collaboration focused on improving understanding of cellular bioprocessing required for the scaled production of therapeutic proteins. The collaboration is supported through the FLexible Interchange Programme (FLIP) Scheme from the Biotechnology and Biological Sciences Research Council (BBSRC). 

The partnership will address the need for greater predictability and certainty in process development and scale-up for the production of protein-based biopharmaceuticals for application in therapeutic areas including cancer and inflammation, according to a Cobra Biologics press announcement.

The agreement will give Cobra access to the UoM’s academic and associated research group. Professor Dickson will have access to Cobra’s production data and operational knowledge of industrial manufacturing processes. Financial terms and terms relating to IP have not been disclosed. 

Source: Cobra Biologics

 

 

 

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content